Compare AbbVie Inc (ABBV) vs Burlington Stores Inc (BURL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Burlington Stores Inc — how do they compare? AbbVie Inc trades at $249.69 (market cap $441.94B), while Burlington Stores Inc trades at $353.4 (market cap $22.59B). The key difference: AbbVie Inc is far larger — about 19.6× Burlington Stores Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.
| ABBV | BURL | |
|---|---|---|
Market Cap | $441.94B | $22.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $372.19 |
52-Week Low | $197.38 | $242.43 |
Enterprise Value | $506.19B | $27.71B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
Burlington Stores (BURL) trades at $353.4, down 4.87% over 24 hours but near its 52-week high, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.01 exceeding expectations. Revenue grew to $10.63 billion in 2025, and the smaller-store strategy is boosting sales productivity. Analyst consensus is overwhelmingly positive, with 94% buy ratings and a $367 price target.
Outlook remains favorable due to consistent earnings outperformance and growth initiatives, though risks include high valuation multiples and competitive retail pressures. The stock offers upside potential aligned with analyst targets, but investors should monitor execution on expansion and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →
